Dr. Sosman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
675 N Saint Clair St
Ste 21-100
Chicago, IL 60611Phone+1 312-695-0990Fax+1 312-695-1106
Education & Training
- University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1986 - 1989
- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1985 - 1986
- University of ChicagoResidency, Pathology-Anatomic and Clinical, 1982 - 1985
- University of ChicagoInternship, Internal Medicine, 1981 - 1982
- Albert Einstein College of MedicineClass of 1981
Certifications & Licensure
- IL State Medical License 1983 - 2026
- TN State Medical License 2001 - 2016
- WI State Medical License 1985 - 1989
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- American Board of Pathology Anatomic Pathology
Clinical Trials
Publications & Presentations
PubMed
- Weight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.Steven D Tran, Noah J Forrest, Vijeeth Guggilla, Geovanni M Perottino, Jodi L Johnson
Journal of Cachexia, Sarcopenia and Muscle. 2025-02-01 - Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24 - 1 citationsAdjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 9...Robert J Motzer, Axel Bex, Paul Russo, Yoshihiko Tomita, Hernan Javier Cutuli
Journal of Clinical Oncology. 2025-01-10
Press Mentions
- Reversing Resistance to PD-1 Inhibitors with Combination Immunotherapy in Patients with Advanced MelanomaApril 8th, 2022
- ECOG-ACRIN Cancer Research Group Melanoma Research Team Led by Michael Atkins, MD, Receives the 2023 Paper of the Year Distinction from the Journal of Clinical OncologyJanuary 19th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: